Katherine Matthay, MD

Dr. Katherine Matthay is the chief of Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital and has been focused for more than 20 years on translational research in neuroblastoma, a deadly childhood cancer. At UCSF, she has developed and led multiple trials using a unique targeted radiopharmaceutical, 131I-MIBG for neuroblastoma.

Dr. Matthay also leads the UCSF Pediatric Malignancies Program and an NIH funded Phase I New Approaches to Neuroblastoma Therapy consortium (NANT) for treatment of relapsed and resistant neuroblastoma.
Websites
Publications
  1. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
  2. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.
  3. Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries.
  4. Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma.
  5. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
  6. A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
  7. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
  8. Association of image-defined risk factors with clinical features, histopathology, and outcomes in neuroblastoma.
  9. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy.
  10. 124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.
  11. Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma.
  12. Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study.
  13. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
  14. Congenital malformation syndromes associated with peripheral neuroblastic tumors: A systematic review.
  15. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
  16. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
  17. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.
  18. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.
  19. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
  20. Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?
  21. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
  22. Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives.
  23. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
  24. Neuroblastoma: clinical and biological approach to risk stratification and treatment.
  25. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
  26. Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography.
  27. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
  28. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
  29. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
  30. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
  31. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
  32. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
  33. Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.
  34. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
  35. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
  36. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
  37. Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma.
  38. Neuroblastoma.
  39. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.
  40. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
  41. Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.
  42. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.
  43. Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?
  44. Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
  45. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma.
  46. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
  47. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
  48. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.
  49. Physician Perspectives on Palliative Care for Children With Neuroblastoma: An International Context.
  50. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
  51. Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma.
  52. Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania.
  53. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
  54. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
  55. Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
  56. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
  57. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
  58. Patient-specific dosimetry using pretherapy [¹²4I]m-iodobenzylguanidine ([¹²4I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.
  59. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.
  60. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
  61. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
  62. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
  63. Reply to N.-K.V. Cheung et al.
  64. Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma.
  65. Drugging MYCN through an allosteric transition in Aurora kinase A.
  66. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
  67. Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit.
  68. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
  69. Symptom assessment in pediatric oncology: how should concordance between children's and parents' reports be evaluated?
  70. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
  71. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.
  72. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.
  73. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
  74. Current treatment and outcome for childhood acute leukemia in Tanzania.
  75. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
  76. Adverse impact of regional lymph node involvement in osteosarcoma.
  77. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
  78. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution.
  79. Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG).
  80. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
  81. Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.
  82. Infections in hospitalized children and young adults with acute leukemia in Morocco.
  83. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
  84. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.
  85. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.
  86. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
  87. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
  88. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.
  89. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
  90. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis.
  91. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
  92. Evaluation of plasma annexin V levels in children and young adults with solid tumors.
  93. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
  94. Promising therapeutic targets in neuroblastoma.
  95. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG).
  96. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.
  97. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.
  98. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
  99. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
  100. Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy.
  101. Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.
  102. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project.
  103. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.
  104. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
  105. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
  106. Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.
  107. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
  108. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project.
  109. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
  110. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
  111. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
  112. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
  113. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
  114. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma.
  115. Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation.
  116. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project.
  117. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.
  118. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
  119. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
  120. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
  121. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.
  122. Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy.
  123. Osteosarcoma in children 5 years of age or younger at initial diagnosis.
  124. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
  125. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
  126. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
  127. An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy.
  128. Ethnic and racial differences in patients with Ewing sarcoma.
  129. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow.
  130. Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: analysis of the surveillance, epidemiology, and end results database.
  131. Neuroblastoma: biology and staging.
  132. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
  133. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
  134. Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy.
  135. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
  136. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.
  137. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
  138. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
  139. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
  140. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
  141. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
  142. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
  143. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.
  144. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
  145. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
  146. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
  147. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.
  148. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
  149. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project.
  150. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors.
  151. Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma.
  152. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
  153. Chemotherapy for neuroblastoma: does it hit the target?
  154. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
  155. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group.
  156. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
  157. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.
  158. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
  159. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
  160. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
  161. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
  162. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
  163. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
  164. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age.
  165. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
  166. Is liver metastasis in neuroblastoma an indication for treatment reduction?
  167. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
  168. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
  169. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.
  170. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.
  171. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
  172. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
  173. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
  174. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
  175. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
  176. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
  177. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study.
  178. Visual attention in long-term survivors of leukemia receiving cranial radiation therapy.
  179. Neuroblastoma: evolving therapies for a disease with many faces.
  180. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.
  181. Immune reconstitution, infectious complications and post transplant supportive care measures after autologous blood and marrow transplantation in children.
  182. Online exclusive: behavioral adjustment of children and adolescents with cancer: teacher, parent, and self-report.
  183. Retinoid therapy of high-risk neuroblastoma.
  184. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
  185. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients.
  186. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
  187. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
  188. Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16).
  189. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.
  190. Development and testing of the School Competency Assessment Scale.
  191. Daycare attendance and risk of childhood acute lymphoblastic leukaemia.
  192. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
  193. Pediatric acute blastic natural killer cell leukemia.
  194. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
  195. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
  196. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
  197. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
  198. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies.
  199. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.
  200. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.
  201. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
  202. Functional and clinical outcomes of limb-sparing therapy for pediatric extremity sarcomas.
  203. Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis.
  204. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG.
  205. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
  206. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study.
  207. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
  208. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination.
  209. Loss of heterozygosity for chromosome 14q in neuroblastoma.
  210. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer
  211. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
  212. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
  213. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
  214. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.
  215. Cognitive consequences and central nervous system injury following treatment for childhood leukemia.
  216. Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
  217. MYCN expression in neuroblastoma: A mixed message?
  218. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.
  219. Is adjuvant therapy ever warranted in localized neuroblastoma.
  220. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.
  221. Intraoperative radiation therapy for high-risk pediatric neuroblastoma.
  222. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
  223. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
  224. Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy.
  225. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
  226. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
  227. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
  228. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
  229. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
  230. The International Neuroblastoma Pathology Classification (the Shimada system).
  231. Molecular biology of neuroblastoma.
  232. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.
  233. Congenital leukemia: successful treatment of a newborn with t(5;11)(q31;q23).
  234. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.
  235. Somatization, anxiety and depression as measures of health-related quality of life of children/adolescents with cancer.
  236. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.
  237. Stage 4S neuroblastoma: what makes it special?
  238. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
  239. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
  240. Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein.
  241. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
  242. Neuroblastoma: biology and therapy.
  243. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
  244. Telomerase expression in primary neuroblastomas.
  245. The International Neuroblastoma Risk Groups (INRG): a preliminary report.
  246. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
  247. Neuroblastoma in adults and adolescents: an indolent course with poor survival.
  248. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.
  249. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma.
  250. Renal cell carcinoma after therapy for neuroblastoma.
  251. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
  252. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco.
  253. Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography.
  254. Toxicities of total-body irradiation for pediatric bone marrow transplantation.
  255. Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience.
  256. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
  257. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy.
  258. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
  259. Neuroblastoma: a clinical challenge and biologic puzzle.
  260. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
  261. Hematology and oncology.
  262. Radiological case of the month. Miliary pulmonary neuroblastoma.
  263. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems.
  264. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
  265. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.
  266. Normal cerebellar MIBG localization. Implications in the interpretation of delayed scans.
  267. Hematology and oncology.
  268. Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma.
  269. Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma.
  270. Optimized diagnostic strategy for neuroblastoma in opsoclonus-myoclonus.
  271. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.
  272. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma.
  273. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.
  274. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma.
  275. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.
  276. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia.
  277. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
  278. Role of radiotherapy in neuroblastoma.
  279. An overview on the treatment of neuroblastoma.
  280. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
  281. Solid tumors in children.
  282. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma.
  283. Response of neuroblastoma to retinoic acid in vitro and in vivo.
  284. Total body irradiation and bone marrow transplantation for immunodeficiency disorders in young children.
  285. Hematologic disorders affecting the lungs.
  286. Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia.
  287. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells.
  288. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy.
  289. Ewing's sarcoma of the mandible.
  290. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment.
  291. Childhood acute lymphoblastic leukemia.
  292. Patient, parent, and physician perspectives on pediatric oncology rounds.
  293. Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition.
  294. Haploidentical bone marrow transplantation using soybean agglutinin-processed, T-depleted marrow.
  295. Lymphocyte reconstitution in children receiving soybean agglutinin T-depleted bone marrow transplants.
  296. Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery.
  297. Bone marrow in children with acute lymphocytic leukemia: MR relaxation times.
  298. Monoclonal antibodies in the diagnosis and treatment of childhood diseases.
  299. New methodology for liposome targeting to specific cells.
  300. Spinal cord compression in a child with acute lymphoblastic leukemia.
  301. Long-term follow-up and booster immunization with polyvalent pneumococcal polysaccharide in patients with sickle cell anemia.
  302. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles.
  303. Antibody-directed liposomes: the development of a cell-specific cytotoxic agent.
  304. Prenatal diagnosis of chronic granulomatous disease.
  305. Increased serum opsonic activity and antibody concentration in patients with sickle cell disease after pneumococcal polysaccharide immunization.
  306. Erythrocyte enzymopathies in the newborn.
  307. Evaluation of the opsonic requirements for phagocytosis of Streptococcus pneumoniae serotypes VII, XIV, and XIX by chemiluminescence assay.
  308. Modification of hemoglobin H disease by sickle trait.
  309. Intracranial hemorrhage in congenital factor VII deficiency.